

IDS/#4
J 1/15/02

PATENT

RECEIVED
JAN 14 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Robert J. Ternansky et al.
Application No. : 09/908,969
Filed : July 18, 2001
For : INHIBITORS OF THE ICE/ced-3 FAMILY OF
CYSTEINE PROTEASES

Art Unit : 1653
Docket No. : 480140.457C1
Date : November 7, 2001

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the 14 references set forth on the attached Form PTO-1449. This application is a continuation-in-part and relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 09/482,813, filed January 13, 2000.

As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Karl R. Hermanns
Registration No. 33,507


KRH:sfl

Enclosures:

Postcard
Form PTO/SB/21
Form PTO-1449
14 Cited References

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

D:\NrPortbl\iManage\SHANEL\231268_1.DOC



GP/1653
#4

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence
after initial filing)

Application Number	09/908,969
Filing Date	July 18, 2001
First Named Inventor	Robert J. Ternansky
Group Art Unit	1653
Examiner Name	Not yet assigned
Attorney Docket No.	480140.457C1

TECH CENTER 1600/2900

JAN 14 2002

RECEIVED



ENCLOSURES (check all that apply)

- | | | |
|--|---|---|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Response
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449
<input checked="" type="checkbox"/> 14 Cited References
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53
<input type="checkbox"/> Response to Missing Parts/Incomplete Application | <input type="checkbox"/> Assignment Papers (for an Application)
<input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Request for Corrected Filing Receipt
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address
<input type="checkbox"/> Declaration
<input type="checkbox"/> Statement under 37 CFR 3.73(b)
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Small Entity Statement
<input type="checkbox"/> Request for Refund | <input type="checkbox"/> CD(s), Number of CD(s) _____
<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Return Receipt Postcard
<input type="checkbox"/> Additional Enclosure(s) (please identify below):


_____ |
|--|---|---|

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Karl R. Hermanns, 33,507	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	11/7/01	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.		
Typed or printed name	Shane F. Lambing	
Signature		Date: 11/7/01

RECEIVED

Sheet 1 of 1

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
480140.457C1APPLICATION NO.
09/908,969JAN 14 2002
TECH CENTER 160012900

INFORMATIONAL CLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Robert J. Ternansky et al.

FILING DATE

July 18, 2001

GROUP ART UNIT

1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,869,519	02/09/99	Karanevsky et al.	514	415	
	AB	5,877,197	03/02/99	Karanevsky et al.	514	397	
	AC	5,968,927	10/19/99	Karanevsky et al.	514	214	
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AG	EP 618 223 A2	10/05/94	EPO		
	AH	EP 623 592 A1	11/09/94	EPO		
	AI	GB 2 292 149 A	02/14/96	Great Britain		
	AJ	JP 11-147873	06/02/99	JPO		X
	AK	WO 97/22619	06/26/97	WIPO		
	AL	WO 00/01666	01/13/00	WIPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Gagliardini et al., "Prevention of Vertebrate Neuronal Death by the <i>crmA</i> Gene," <i>Science</i> 263:826-828, February 11, 1994.
	AN	Marx, "Cell Death Studies Yield Cancer Clues," <i>Science</i> 259:760-761, February 5, 1993.
	AO	Okamoto et al., "Peptide Based Interleukin-1 β Converting Enzyme (ICE) Inhibitors: Synthesis, Structure Activity Relationships and Crystallographic Study of the ICE-inhibitor Complex," <i>Chem. Pharm. Bull.</i> 47(1):11-21, January 1999.
	AP	Sleath et al., "Substrate Specificity of the Protease That Processes Human Interleukin-1 β ," <i>The Journal of Biological Chemistry</i> 265(24):14526-14528, August 25, 1990.
	AQ	Patent Abstracts of Japan, Abstract of JP 11-147873, vol. 1999, no. 11, September 30, 1999.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).